Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement
Conditions
Interventions
4D-310
Locations
4
Australia
Royal Melbourne Hospital
Melbourne, Australia
Royal Perth Hospital
Perth, Australia
Westmead Hospital
Westmead, Australia
Taipei Veterans General Hospital
Taipei, Taiwan
Start Date
October 16, 2022
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2030
Last Updated
February 21, 2025
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06776419
NCT06081062
Lead Sponsor
4D Molecular Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions